IDEXX Laboratories, Inc. - 10-Q Summary
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for IDEXX Laboratories, Inc., a provider of diagnostic products and services for the veterinary, water quality, and food diagnostics markets. The report covers the quarterly and nine-month periods ended September 30, 2006. The company operates through three primary segments: Companion Animal Group (CAG), Water, and Food Diagnostics Group (FDG).
Key Financial Metrics
(All figures in thousands, except per share data)
| Metric | Three Months Ended Sep 30, 2006 | Nine Months Ended Sep 30, 2006 |
|---|---|---|
| Total Revenue | $187,380 | $546,908 |
| Gross Profit | $98,199 (52.4% margin) | $283,260 (51.8% margin) |
| Operating Income | $34,462 (18.4% margin) | $98,463 (18.0% margin) |
| Net Income | $24,953 | $69,006 |
| Diluted EPS | $0.76 | $2.09 |
| Cash & Equivalents | $50,950 | $50,950 (Balance Sheet) |
| Short-term Investments | $43,641 | $43,641 (Balance Sheet) |
| Long-term Debt | $6,625 | $6,625 (Balance Sheet) |
| Operating Cash Flow (9mo) | N/A | $71,412 |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 19% ($29.3M) for the quarter and 16% ($75.8M) for the nine months compared to the prior year periods. Growth was driven by all three segments, with CAG contributing the largest absolute increase.
- Accounting Change (SFAS 123(R)): The company adopted SFAS No. 123(R) on January 1, 2006, requiring fair-value accounting for share-based compensation. This resulted in an additional operating expense of $2.1M for the quarter and $6.8M for the nine months, which was not allocated to operating segments but categorized as "Other."
- Acquisitions: The company completed several acquisitions in 2006, including veterinary reference laboratories and digital radiography assets, contributing to revenue growth and goodwill increases.
- Facility Purchase: In May 2006, the company purchased its Westbrook, Maine headquarters for $11.5M cash and assumed a $6.5M mortgage, impacting investing cash flows and interest expense.
- Inventory Build-up: Operating cash flow was negatively impacted by a $23.1M increase in inventory, largely due to timing of slide purchases and preparation for supplier transitions.
Guidance, Outlook, and Risks
- Capital Expenditures: Management anticipates total capital expenditures of $55M to $60M for 2006. Preliminary projections for 2007-2008 facility renovations are approximately $50M.
- Share Repurchases: The company has 857,000 shares remaining under its $16M share repurchase authorization. It repurchased 115,500 shares in Q3 2006.
- Regulatory Risks: The FDA determined a new animal drug application (NADA) for a long-acting feline antibiotic was incomplete; the company decided not to pursue approval. Management does not believe this will materially affect operations.
- Supply Chain Risks: The company relies on limited sources for key components (e.g., VetTest slides, VetAutoread analyzers). Minimum purchase obligations exist, creating risk if demand falls short.
- Foreign Currency: International revenue is significant. An appreciation of the U.S. dollar could reduce operating margins. The company uses forward contracts to hedge exposure.
Investor Verification Checklist
- Inventory Levels: Verify the rationale for the $23.1M increase in inventory and the timing of supplier transitions to ensure no obsolescence risk.
- Share-Based Compensation Impact: Confirm the ongoing impact of SFAS 123(R) on future operating margins and the $17.5M of unrecognized compensation cost.
- Acquisition Integration: Monitor the performance of recent acquisitions (veterinary labs, digital radiography) to ensure they meet revenue and margin expectations.
- Regulatory Status: Track the status of other pending FDA/USDA approvals for new pharmaceutical and diagnostic products.
- Debt Service: Review the impact of the new $6.5M mortgage on future interest expenses and cash flow.